The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant cisplatin based therapy in bladder cancer: Is less enough?
 
Saqib Abbasi
No Relationships to Disclose
 
Mohammed Al-Jumayli
No Relationships to Disclose
 
Hannah Hildebrand
No Relationships to Disclose
 
Elizabeth Marie Wulff-Burchfield
Stock and Other Ownership Interests - Immunomedics (I); Nektar (I)
 
Eugene K. Lee
No Relationships to Disclose
 
John A Taylor
Honoraria - ASCO; Bristol-Myers Squibb; Photocure
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Ferring
Patents, Royalties, Other Intellectual Property - PCT/US11/21721. Use of Isoxazoline compounds and compositions in bladder cancer. Inventors: Taylor JA and Sielecki TM
Other Relationship - Photocure
 
Jeffrey Holzbeierlein
Research Funding - MDxHealth (Inst)
 
Grace Martin
Consulting or Advisory Role - Clovis Oncology
 
Rahul Atul Parikh
Stock and Other Ownership Interests - Abbvie (I); Immunomedics (I)
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Seattle Genetics/Astellas
Research Funding - Saladax Biomedical; Taiho Pharmaceutical
Patents, Royalties, Other Intellectual Property - Patents on DNA repair pathways in cancer. I do not receive any royalties for the same.
Travel, Accommodations, Expenses - AstraZeneca; Seagen